Ad is loading...
AKBA
Price
$1.82
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
110 days until earnings call
ALLK
Price
$0.91
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
102 days until earnings call
Ad is loading...

AKBA vs ALLK

Header iconAKBA vs ALLK Comparison
Open Charts AKBA vs ALLKBanner chart's image
Akebia Therapeutics
Price$1.82
Change-$0.00 (-0.00%)
Volume$1.44M
CapitalizationN/A
Allakos
Price$0.91
Change-$0.00 (-0.00%)
Volume$453.13K
CapitalizationN/A
AKBA vs ALLK Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ALLK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
AKBA vs. ALLK commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and ALLK is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (AKBA: $1.82 vs. ALLK: $0.91)
Brand notoriety: AKBA and ALLK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 77% vs. ALLK: 43%
Market capitalization -- AKBA: $397.09M vs. ALLK: $83.91M
AKBA [@Biotechnology] is valued at $397.09M. ALLK’s [@Biotechnology] market capitalization is $83.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileALLK’s FA Score has 1 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • ALLK’s FA Score: 1 green, 4 red.
According to our system of comparison, ALLK is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 5 TA indicator(s) are bullish while ALLK’s TA Score has 5 bullish TA indicator(s).

  • AKBA’s TA Score: 5 bullish, 6 bearish.
  • ALLK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ALLK is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а -2.15% price change this week, while ALLK (@Biotechnology) price change was -23.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

AKBA is expected to report earnings on Mar 12, 2025.

ALLK is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($410M) has a higher market cap than ALLK($78.3M). AKBA YTD gains are higher at: 46.774 vs. ALLK (-66.780). AKBA has higher annual earnings (EBITDA): 4.3M vs. ALLK (-154.72M). ALLK has more cash in the bank: 92.7M vs. AKBA (34M). ALLK has less debt than AKBA: ALLK (39M) vs AKBA (48.6M). AKBA has higher revenues than ALLK: AKBA (170M) vs ALLK (0).
AKBAALLKAKBA / ALLK
Capitalization410M78.3M524%
EBITDA4.3M-154.72M-3%
Gain YTD46.774-66.780-70%
P/E RatioN/AN/A-
Revenue170M0-
Total Cash34M92.7M37%
Total Debt48.6M39M125%
FUNDAMENTALS RATINGS
AKBA vs ALLK: Fundamental Ratings
AKBA
ALLK
OUTLOOK RATING
1..100
7460
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3754
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALLK's Valuation (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (74) in the Biotechnology industry. This means that ALLK’s stock grew somewhat faster than AKBA’s over the last 12 months.

ALLK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ALLK’s stock grew similarly to AKBA’s over the last 12 months.

ALLK's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ALLK’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (37) in the Biotechnology industry is in the same range as ALLK (54) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to ALLK’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLK (100) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to ALLK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBAALLK
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 17 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ALLK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEQIX16.750.21
+1.27%
Glenmede Equity Income
MECVX15.480.14
+0.91%
NYLI Epoch Capital Growth Investor Class
PSLGX154.221.18
+0.77%
Putnam Sustainable Leaders R6
GRMIX28.520.16
+0.56%
Nationwide S&P 500 Index R6
INFFX9.60N/A
N/A
Tortoise Energy Infrastructure and Inc C

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+1.68%
ABOS - AKBA
43%
Loosely correlated
-2.53%
BEAM - AKBA
41%
Loosely correlated
-3.72%
ABCL - AKBA
40%
Loosely correlated
+1.87%
INZY - AKBA
40%
Loosely correlated
-3.58%
KOD - AKBA
36%
Loosely correlated
+1.90%
More

ALLK and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLK has been loosely correlated with AXON. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLK jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLK
1D Price
Change %
ALLK100%
-3.44%
AXON - ALLK
38%
Loosely correlated
+3.52%
PRME - ALLK
38%
Loosely correlated
-0.67%
ENSC - ALLK
34%
Loosely correlated
-9.65%
AKBA - ALLK
34%
Loosely correlated
+1.68%
IMCR - ALLK
33%
Loosely correlated
-0.93%
More